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Abstract: The presence of BRAF variant V595E, as well as an increased cyclooxygenase-2 (COX-2)
expression in canine transitional cell carcinoma (TCC) are well-described in the literature. The aim of
the present study was to investigate the correlation between breed (terrier versus non-terrier dogs),
histological grade, COX-2 expression, and BRAF mutation in canine TCC. Therefore, transmural
TCC biopsies from 65 dogs (15 terriers, 50 non-terriers) were graded histologically into low- and
high-grade. Immunohistochemical evaluation of the intensity of COX-2 expression was performed
using an immunoreactive score (IRS). Exon 15 of chromosome 16 was examined for the BRAF variant
c.1799T>A by TaqMan® SNP assay. TCC was low-grade in 20 cases (one terrier, 19 non-terriers) and
high-grade in 45 cases (14 terriers, 31 non-terriers). Contrary to humans, histological grade was
not significantly correlated to the intensity of COX-2 expression. BRAF mutation was detected in
11/15 (73%) TCC of terriers and in 18/50 (36%) TCC of non-terriers. Histological grade and BRAF
mutation were not correlated significantly (p = 0.2912). Terriers had a considerably higher prevalence
of high-grade tumors (p < 0.0001), as well as of BRAF mutation (p ≤ 0.05) compared to non-terriers.
In non-terriers, neoplasms with BRAF mutation showed a significantly higher intensity of COX-2
expression than those without BRAF mutation (p≤ 0.05). In conclusion, in contrast to humans, testing
for BRAF mutation in canine TCC is a sensitive diagnostic method especially in terriers (73%) and
may be recommended as a screening test. However, evidence of BRAF mutation in canine TCC is not
a predictor for the histological grade. Moreover, a positive correlation between histological grade
and the intensity of COX-2 expression was not found. Further studies are necessary to clarify the
clinical and prognostic relevance of the elevated intensity of COX-2 expression of TCC with BRAF
mutation detected in non-terriers.
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1. Introduction
Transitional cell carcinoma (TCC), also referred to as urothelial carcinoma, is the most common
malignant tumor of the canine urinary tract. The breed-associated risk includes a 21-fold increased
risk in Scottish terriers and a 3.0–6.5-fold increased risk in Eskimo dogs, Shetland sheepdogs, West
Highland white terriers, keeshonds, samoyeds, and beagles compared to mixed breed dogs [1].
The mean age of dogs at time of diagnosis is 11 years [2]. Several studies have confirmed the
increased risk of bladder cancer in female dogs and in neutered ones compared to intact dogs of
the same gender [3]. Interestingly, in dogs with high breed-associated risk, the sex predilection is
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less pronounced [4]. High-grade TCC is reported in more than 90% of dogs suffering from TCC [2].
Metastasis at the time of diagnosis is described in 37% of dogs [5]. In dogs suffering from TCC that
only undergo surgical therapy, a longer mean survival time has rarely been observed, in contrast
to dogs with TCC that have been treated with additional therapies [6]. Thus, other treatments are
recommended, such as radiotherapy, transurethral diode laser resection, intralesional interleukin-2
injection, classic chemotherapy, or metronomic chemotherapy with continuous oral administration
of chlorambucil [6]. Knapp et al. reported that the nonselective cyclooxygenase (COX) inhibitor
piroxicam significantly enhanced the activity of vinblastine, a chemotherapeutic agent, in dogs
with TCC [7]. However, the complex mechanisms of the effect of COX inhibitors are still poorly
understood [8]. Mohammed et al. [9] reported a reduction in tumor volume in 12 of 18 dogs due
to induction of apoptosis caused by piroxicam. COX enzymes catalyze the rate-limiting step of
prostaglandin biosynthesis and are involved in inhibiting apoptosis, promoting cell proliferation,
stimulating angiogenesis, and decreasing immunity [10]. In general, COX-1 is present in several
normal tissues, and COX-2 is expressed in multiple neoplasms and inflammatory cells [11]. Regular
expression of COX-1 has been described in normal urinary bladder epithelium, but intense COX-2
expression was found in canine TCC [12]. There are different examination methods to evaluate COX-2
expression: Khan et al. estimated the percentage of COX-2 positive neoplastic cells and their staining
intensity, but did not use a scoring system [12]. Lee et al. reported increased COX-2 expression in
57.7% of canine TCC based only on the percentage of positive neoplastic cells, but not including
the various expression intensities within one TCC [13]. Knottenbelt et al. reported positive COX-2
expression in up to 100% of the canine TCC examined considering the different expression intensities
and percentages of positive cells within one TCC, but without calculating any scores nor describing
whether neoplastic and/or inflammatory cells were taken into account [8]. Mutsaers et al. [14] did not
believe the intensity of COX-2 expression was a useful predictive factor for a response to piroxicam.
In his study, he included the percentage of neoplastic cells with COX-2 immunoreactivity, as well
as the different staining intensities, but did not work with any scoring system. Furthermore, he
only evaluated the area of the highest COX-2 staining (“hot spot”) without considering areas with
lower COX-2 expression. This may have caused an overestimation of the COX-2 expression in the
investigated TCC and could be the reason for the low response to piroxicam that was observed, even
though COX-2 expression was high. In vitro, the selective COX-2 inhibitor mavacoxib exerts antitumor
effects independent of COX-2 expression levels in canine, as well as in human cell lines [15]. However,
in vivo studies addressing this finding are not available so far. The different studies regarding the
intensity of COX-2 expression are therefore not comparable and should be interpreted carefully.
In humans, 2% of all cancers are TCC [2]. The mean age at time of diagnosis is 65 years [2],
and a gender predisposition is described for men [16]. The majority of bladder cancers in humans
are classified as superficial low-grade TCC [3]. However, in invasive high-grade TCC, metastasis
is reported in 5–20% of cases at the time of diagnosis [16]. The COX-2 expression in humans is a
marker of invasion, recurrence, and a short survival time [17–19]. It is particularly expressed in
high-grade forms, possibly playing a role in the differentiation of this tumor and being a valuable
target molecule in the treatment of TCC [20]. In the standard treatment of human TCC, transurethral
resection is performed first [21]. Post-transurethral resection, intravesical therapy with bacillus
Calmette-Guérin, an attenuated mycobacterium with antitumor activity when administered as an
intravesical instillation [22], has been shown to reduce the risk of recurrence. Alternative chemotherapy
agents, such as mitomycin C, doxorubicin, epirubicin, gemcitabine, and thiotepa, can be used for
intravesical instillation [23]. For patients with inoperable, locally-advanced metastatic TCC, systemic
chemotherapy is the standard initial treatment [24]. In the second-line setting, immunotherapy with
immune check point inhibitors is now the standard of care [24].
Mutations of BRAF genes (B-isoform of rapidly accelerated fibrosarcoma) are a common cause of
tumor formation in humans and lead to abnormal proliferation and differentiation of cells [25]. Studies
from the U.S. have shown that BRAF variant V595E (cBRAF reference sequence ENSCAFT00000006306),
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which corresponds to the BRAF (V600E) variant in humans, can be found in tumor cells of 65–85%
of dogs with TCC [26–29]. In humans, as well as in dogs, BRAF mutation is a thymine-to-adenine
transversion in exon 15 of chromosome 16, resulting in the amino acid substitution from valine to
glutamic acid [30]. This somatic mutation was specifically found in canine TCC and prostate tumors,
but rarely in other canine tumors [31]. A breed predisposition showing a BRAF mutation in cases of
TCC was found for terrier breeds [6]. In humans, only 1% of TCC is caused by BRAF mutation [32],
and this mutation appeared to be infrequent in TCC [31]. However, BRAF mutation plays a crucial
role in human cancer, and about 7% of all cancer cases carry this mutation [33]. It is frequently
mutated in melanomas (50%) [34], papillary thyroid cancers (45%) [35], colon cancers (10%) [36], and
in non-small-cell lung cancers (10%) [37]. A positive correlation of COX-2 expression and the presence
of BRAF mutation were reported in human colorectal cancer [38], but have not been investigated in
dogs. Therapeutic concepts against human tumors induced by BRAF mutation include MAP kinase
inhibitors, which are used in human medicine [39]. Bourn and Cekanova reported a potentiated MAP
kinase inhibitor therapy in vitro in combination with COX inhibitors in human, as well as in canine
TCC cell lines [40]. However, MAP kinase inhibitors are not currently available for dogs.
Positive correlations between histological grade and COX-2 expression, as well as between COX-2
expression and the presence of BRAF mutation were presumed for canine TCC. Therefore, the aims
of this study were to determine any correlation between histological grade and intensity of COX-2
expression, between the histological grade and the presence of BRAF mutation, as well as between
the presence of BRAF mutation and the intensity of COX-2 expression in canine TCC. Furthermore,
the differences in histological grade, intensity of COX-2 expression, and BRAF mutation between
terriers and non-terrier breeds were evaluated.
2. Materials and Methods
2.1. Study Design
TCC biopsy samples from 65 dogs submitted for routine diagnostics were selected over a
seven-year period (2012–2018) (Tables 1 and 2). Inclusion criteria were: transmural biopsy (comprising
mucosa, submucosa, and muscularis) and full information about breed, sex, and age of the dogs.
The animals were between 6 and 14 years old (median 11 years). The cohort included 23 intact
and 22 spayed females, as well as 12 intact and 8 castrated male dogs. Included were 15 terrier
breeds according to the Fédération Cynologique Internationale (FCI) Group 3 (Section 1, large- and
medium-sized Terriers: 1 Airedale terrier, 1 Fox terrier; Section 2, small-sized terriers: 5 Scottish
terriers, 4 Jack Russel terriers, 3 West Highland white terriers; Section 4, toy tTerriers: 1 Yorkshire
terrier) and 50 dogs of non-terrier breeds (21 mongrels, 4 beagles, 3 Shetland sheepdogs, 3 poodles,
3 Bernese mountain dogs, and 16 other breeds).
Table 1. Terriers: signalment, histological grade, cyclooxygenase-2 expression, and BRAF mutation in
transitional cell carcinoma (n = 15).
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Table 1. Cont.






(n = 1) 10 FN high 4.1 +
Fox terrier
(n = 1) 12 FN high 3.8 +
Welsh terrier
(n = 1) 12 FN high 4.7 −
Yorkshire terrier
(n = 1) 11 F high 7.1 +
+ = BRAF mutation positive, − = BRAF mutation negative, COX = cyclooxygenase, F = female, FN = neutered
female, IRS = immunoreactive score, M = male, MN = neutered male.
Table 2. Non-terrier breeds: signalment, histological grade, cyclooxygenase-2 expression, and BRAF
mutation in transitional cell carcinoma (n = 50).












































































(n = 1) 11 F low 5.0 −
Rottweiler
(n = 1) 10 M low 1.0 −
Podenco
(n = 1) 11 MN low 7.8 +
Siberian husky
(n = 1) 12 MN low 1.1 +
German wirehaired pointer
(n = 1) 8 F high 0.8 −
Great dane
(n = 1) 7 M high 0.9 −
Bracke
(n = 1) 11 FN high 0.2 −
French bulldog
(n = 1) 10 F high 4.1 −
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Table 2. Cont.








(n = 1) 12 FN high 9.8 −
Bichon frise
(n = 1) 11 MN high 0.3 −
Border collie
(n = 1) 12 M high 2.0 −
+ = BRAF mutation positive, − = BRAF mutation negative, COX = cyclooxygenase, F = female, FN = neutered
female, IRS = immunoreactive score, M = male, MN = neutered male.
2.2. Histology
The formalin-fixed tissue specimens (min: 0.5 × 0.4 × 0.4 mm, max: 6.5 × 4.4 × 1.5 mm) were
dehydrated through a graded series of ethanols (up to 96% ethanol) and embedded in paraplast
(SAV-liquid Production GmbH, Flintsbach am Inn, Germany; PFNP-20-5858-1). Slices (3–4 µm) were
mounted on coated slides (SuperFrost® Plus, Menzel Gläser, Thermo Scientific, Waltham, MA USA).
The standard hemalaun-eosin stain (HE) was performed [41]. Transitional cell carcinomas were
diagnosed routinely and graded according to Meuten and Meuten [42] into low- or high-grade. Mitotic
figures were counted in 10 high-power fields (HPFs; 400×; area: 68,700 µm2, Nikon Eclipse E200
microscope; Nikon, Tokyo, Japan) in areas with the highest mitotic activity, and the mean value
was calculated.
Low-grade TCC was characterized by mild to moderate cellular atypia, mild nuclear abnormalities,
rare to no mitoses, mild to no invasion of the submucosa with intact basement membrane, or no
invasion into blood and lymphatic vessels.
In contrast, epithelial tumor cells of high-grade TCC showed loss of cell polarity, disorganized
growth, marked cellular atypia, marked nuclear pleomorphism, or numerous mitoses. They penetrated
the basement membrane and invaded deeper structures. Furthermore, they attached to and invaded
blood or lymphatic vessels. In general, one characteristic feature of high-grade TCC is sufficient to
define it as high-grade, but mostly numerous signs of malignancy coexist in canine TCC. The growth
pattern was classified as papillary (projecting into the lumen) or non-papillary (sessile or flat) [42].
2.3. Immunohistochemistry
Tissue sections were mounted on SuperFrost slides. Pre-treatment at a high temperature (96 ◦C)
with EDTA buffer (pH 9.0) was performed for 30 min. Cross-reacting monoclonal mouse anti-human
COX-2 (1:100, clone cx-294, Dako, # 3617) diluted in antibody diluent (Zytomed, # ZUC025-100) served
as the primary antibody. Canine TCC specimens were used as positive control tissues. Subsequently,
sections were incubated overnight at 4 ◦C with the primary antibodies or a non-related isotype-matched
antibody (negative control) [43]. As detection system, Dako EnVision+System-HRP (diaminobenzidine
tetrahydrochloride (DAB)) (Dako, # K4006), was applied for 30 min at room temperature. All slides
were finally developed in DAB (diaminobenzidine tetrahydrochloride, Dako, # K4006) for 10 min at
room temperature and counterstained with hemalum.
Neoplastic and inflammatory cells were histologically identified. COX-2 expression was partly
seen in the inflammatory and neoplastic cells, but not in the normal bladder epithelium. For this
study, however, only neoplastic cells were further examined. In each specimen, the intensity of
COX-2 expression of the neoplastic cells showed a great range, in some cases reaching from mild to
marked in one sample. Thus, a modified version of the immunoreactive score (IRS) published by
Hoffmann et al. [44] was used. For this, the percentages of positive neoplastic cells (PP) at the different
staining intensities (SI) were assessed in the whole slide. The different staining intensities were scored
with values ranging from 0–10 with the staining intensity being defined as: 0 = absence of staining,
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0.5 = slight, 1 = mild, 5 = moderate, and 10 = most intense staining. The IRS was calculated as a sum








n = index, PP = percentage of positive cells, SI = staining intensity.
The TCC were graded based on the COX-2 expression intensity (IRS) into minimal (IRS ≤ 0.9),
mild (IRS > 0.9 to ≤ 3.3), moderate (IRS > 3.3 to ≤ 6.3), and marked (IRS > 6.3).
2.4. BRAF Mutation Analysis
DNA isolation from paraffin-embedded tissue was performed using a QIAamp DNA FFPE Tissue
Kit (Qiagen, Hilden, Germany; # 56404). This kit uses a column-based method designed for purifying
DNA from formalin-fixed, paraffin-embedded tissue sections. To do so, paraffin was dissolved in
xylene. The sample was lysed under denaturing conditions with a short proteinase K digestion.
After that, incubation at 90 ◦C reversed formalin cross-linking. DNA bound to the membrane of
the column in a reaction tube, while contaminants flowed through. DNA was eluted and used
for the subsequent PCR reaction. Exon 15 was examined for the presence of the mutation (BRAF
variant c.1799T>A) by the TaqMan® SNP assay (Applied Biosystems, Foster City, CA, USA, # 4332075)
using FastStart Essential DNA Probes Master and LightCycler 480 II (Hoffmann-La Roche, Basel,
Switzerland). The genotyping assay was performed using specific, provided PCR primers (forward
primer TGGGACCCACTCCATCGA, reverse primer CATGAAGACCTCACAGTAAAAATAGGTGAT,
no canine-specific primers) and probes (the probe sequence for detection of the wild-type allele was
TAGCCACAGTGAAATC labelled with VIC™ fluorescent dye, the probe sequence for detection of the
mutant allele was CCACAGAGAAATC with FAM™ fluorescent dye). Cycling conditions were 10 min
at 95 ◦C, followed by 40 cycles of 15 s at 95 ◦C and 1 min at 60 ◦C.
2.5. Statistical Analyses
Statistical significance analyses were performed using GraphPad Prism Version 7.03 for Windows,
GraphPad Software (La Jolla, CA, USA) www.graphpad.com. Data concerning correlations between
breeds, histological grade, and BRAF mutation (nominal data) were tested using Fisher’s exact test.
Ordinal data (IRS for COX-2 expression) were examined for the Gaussian distribution using the
Shapiro–Wilk normality test. Non-parametric data (IRS for COX-2 expression) were verified using the
Mann–Whitney U test. Values ≤0.05 were considered as significant.
3. Results
3.1. Histology
Histological grading resulted in 20 (1/15 terriers, 19/50 non-terriers) low- and 45 (14/15 terriers,
31/50 non-terriers) high-grade TCC. Dogs with low-grade TCC (Figure 1a) were between seven and
14 years (median 11 years) old. The growth pattern was papillary in 13 and non-papillary in seven
cases. A mild invasion of the submucosa without destruction of the basement membrane was seen in
11/20 and no invasion of the submucosa in 9/20 cases. Anisocytosis and anisokaryosis were mild, and
few mitoses/HPF were counted. Vascular attachment was found in 6/20 cases, but vascular invasion
was not seen in any of the samples.
Dogs with high-grade TCC (Figure 1b) were also, on average, 11 years old (range: 6–13 years).
The growth pattern was non-papillary in 25 cases and papillary in 20 cases. The neoplasms massively
invaded either the submucosa (6/45) or submucosa and muscularis (39/45). Anisocytosis and
anisokaryosis were moderate to marked, and several mitoses/HPF were counted. Vascular attachment
(35/45) and vascular invasion (23/45) were identified in many cases.
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An age- or sex-related difference between low- and high-grade TCC was not detectable. In terriers
(p < 0.0001), as well as in non-terriers (p ≤ 0.05), high-grade TCC was significantly more prevalent
than low-grade TCC (Figure 2). Furthermore, high-grade TCC was considerably more often found in
terriers than in non-terriers (p ≤ 0.05).
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Figure 2. Correlation between histological grade and breed: A significantly higher percentage of
high-grade transitional cell carcinoma (TCC) compared to low-grade TCC was observed in terriers
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3.2. COX-2 Immunohistochemistry
Normal transitional cell epithelium was not labelled by anti-COX-2 antibody (Figure 3a).
Inflammatory cells and neoplastic cells were positive. The intensity of COX-2 expression of the
neoplastic cells varied strongly within each specimen (Figure 3b). Calculation of the COX-2 expression
intensity (IRS) resulted in TCC being labelled as follows: nine minimal (IRS 0.2–0.9) (Figure 3c), 20 mild
(IRS 1.0–3. ) (Figure 3d), 24 moderate (IRS .6–6.3) (Figure 3e), and 13 marked (IRS 6.6–9.8) (Figur 3f).
COX-2 IRS was statistically not normally distributed. There was no age- or sex-related differ nce in
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COX-2 expression detectable. No significant (p = 0.9859) difference was found between COX-2 IRS of
high-grade TCC (median 3.8, range: 0.2–9.8) and low-grade TCC (median 3.8, range: 0.3–7.8).
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3.3. BRAF Mutation 
Genetic testing of 65 TCC showed BRAF mutation in 29 cases (11/15 terriers, 18/50 non-terriers) 
and the wild-type in 36 dogs (4/15 terriers, 32/50 non-terriers) (Figure 4). There was no significant (p 
= 0.2912) difference in the prevalence of BRAF mutation between low- and high-grade TCC. BRAF 
mutation was significantly (p ≤ 0.05) more often found in TCC of Terriers than in TCC of non-terrier 
breeds (Figure 5). In terriers, COX-2 expression intensity did not show a significant difference  
(p = 0.3915) between neoplasms with or without BRAF mutation. In contrast, in non-terrier breeds, 
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Figure 3. l oxygenase-2 i munohistochemistry. (a) Normal bladd r epithelium (E) of a
10-year-old female mongrel. There is no appare t l ase-2 expre sion (COX-2, bar = 25 µm).
(b) High-grade transitional cell c rci fro an 1-year-old female Scottish terrier with an IRS
of 7.6. Intensity of cyclooxygenase-2 expression varied from mild (*) to marked (#) within the
specimen (COX-2, bar = 100 µm). (c) Area with minimal intensity of cyclooxygenase-2 expression
in high-grade transitional cell carcinoma from an 11-year-old castrated female bracke (COX-2, bar =
25 µm). (d) Area with mild intensity of cyclooxygenase-2 expression in low-grade transitional cell
carcinoma from a 12-year-old castrated female beagle (COX-2, bar = 25 µm). (e) Area with moderate
intensity of cyclooxygenase-2 expression in high-grade transitional cell carcinoma from a 13-year-old
castrated male mongrel (COX-2, bar = 25 µm). (f) Area with marked intensity of cyclooxygenase-2
expression in low-grade transitional cell carcinoma from an 11-year-old castrated male podenco (COX-2,
bar = 25 µm).
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3.3. BRAF Mutation
Genetic testing of 65 TCC showed BRAF mutation in 29 cases (11/15 terriers, 18/50 non-terriers)
and the wild-type in 36 dogs (4/15 terriers, 32/50 non-terriers) (Figure 4). There was no significant
(p = 0.2912) difference in the prevalence of BRAF mutation between low- and high-grade TCC. BRAF
mutation was significantly (p ≤ 0.05) more often found in TCC of Terriers than in TCC of non-terrier
breeds (Figure 5). In terriers, COX-2 expression intensity did not show a significant difference
(p = 0.3915) between neoplasms with or without BRAF mutation. In contrast, in non-terrier breeds,
TCC with BRAF mutation had a significantly (p ≤ 0.05) higher COX-2 expression than TCC without
BRAF mutation. TCC without BRAF mutation had a higher COX-2 expression in terriers than TCC
without BRAF mutation had in non-terriers, but this difference was not significant (p = 0.4154). There
was also no significant (p = 0.0579) difference in the intensity of COX-2 expression between BRAF
mutation-positive TCC in terriers and BRAF mutation-positive TCC in non-terriers (Figure 6).
In conclusion, this interpretation algorithm (Figure 7) can be derived from the data of transmural
biopsies in our study: In cases of TCC with BRAF mutation in terriers, a high-grade tumor with
increased COX-2 expression is most likely. Cases of TCC without BRAF mutation are rare in the
analyzed terrier breeds. Irrespective of the BRAF mutation status, in the case of TCC in a non-terrier,
high-grade TCC, is more likely than low-grade TCC, just as it is in terriers. However, since terriers
suffer significantly more often from high-grade TCC than non-terriers, it cannot be assumed that the
high-grade morphology in non-terrier TCC is the most likely. Therefore, the histological grade of
TCC in non-terriers should always be verified in addition by histological examination. As in terriers,
an increased COX-2 expression in TCC in non-terriers is only likely if a positive BRAF mutation
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4. Discussion
To the authors’ knowledge, this is the first study in dogs investigating the histological grade of
TCC, the intensity of COX-2 expression, and the presence of the BRAF mutation with a special focus
on breed predilection of terriers.
Although canine and human TCC are largely and histopathologically very similar [45], there are
some remarkable differences regarding the sex predisposition, histological grade, and prevalence of
BRAF mutation, as well as a notable correlation of histological grade and intensity of COX-2 expression.
A known sex predisposition for female dogs suffering from TCC [3] was confirmed by the present study.
In humans, a gender predisposition is described for men [16]. Furthermore, canine TCC shows mostly
high-grade malignancy [2,42]. This was confirmed by the present data and is contrary to the situation in
humans where the majority of TCC is classified as superficial low-grade [3]. Another difference between
both species is the prevalence of BRAF mutation in TCC. While infrequently in human TCC (<1%) [31],
BRAF mutation is often detected in canine TCC [26–29,39]. Additional BRAF mutations in exons 11
and 14 were reported in human cancers [46], but until now, not in dogs. In humans, a significantly
higher intensity of COX-2 expression is known in high-grade TCC [17,19]. In the present study, we
found no considerable difference in the intensity of COX-2 expression between low- and high-grade
canine TCC. However, a significant positive correlation was found between the presence of BRAF
mutation and the intensity of COX-2 expression in TCC in non-terrier breeds. This finding is consistent
with the results of a study in humans describing higher COX-2 expression in BRAF mutation-positive
colorectal cancer than in BRAF mutation-negative intestinal tissue [38]. The authors of that study
suggested that the correlation between BRAF mutation and COX-2 is mediated by insulin-like growth
factor receptor 1 (IGF-1R) as shown in human pancreatic carcinomas, where IGF-1R is enhanced by the
BRAF mutation and mediates COX-2 expression selectively via the MAPK/(Erk-1/2) pathway [47].
Whether this mechanism is also present in canine TCC requires verification. It is possible that the
correlation of BRAF mutation and the intensity of COX-2 expression in terrier breeds would have
reached significance if more cases had been included in this group. Because of the high heterogeneity
of the studies addressing COX-2 expression intensity, which has already been discussed, it seems
difficult to compare the various results. It is therefore still questionable if COX-2 expression is a
predictive factor for the response of TCC to COX-2 inhibitors [48]. Additional research, including the
development of in vitro cell systems, is needed to determine if COX-2 expression can be used as a
reliable prognostic factor and as a definite therapeutic target in animal cancers [48]. Overall, the use of
COX-2 inhibitors in the treatment of canine, as well as of human TCC is common, and the efficiency
has been proven in numerous studies [40,49–51].
Terriers have a well-documented breed predisposition for TCC [1]. It has to be taken into
consideration that histological grading of urinary bladder biopsies requires transmural samples of
sufficient size to evaluate intramural and intravascular invasion [42]. In endoscopy, sampling of
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biopsies with sufficient size is sometimes not possible. The present study shows that high-grade TCC
is significantly more common in terriers than in non-terrier breeds. It can be concluded from these
findings that high-grade TCC can be assumed as statistically most likely in terriers, even if histological
grading may not be possible if the size of the specimen is too small.
Our results confirm the results by Pantke et al. who reported a significantly higher prevalence of
BRAF mutation in TCC in terriers compared to TCC in non-terrier breeds [6]. This may be the reason
for the high breed-associated risk regarding TCC in terriers [1] and may result from a specific genetic
polymorphism in this breed. Such polymorphisms are responsible for the gender predisposition
regarding BRAF mutation of melanomas in humans [52]. Whether such polymorphisms exist in dogs
and if they make the BRAF gene susceptible to mutagenic factors could be the subject of further
studies. However, Aupperle-Lellbach et al. (18 terriers and 48 non-terrier breeds) and Decker et al.
(18 terriers, 38 non-terrier breeds, and 8 non-specified breeds) did not identify a breed disposition
for BRAF mutation [26,27]. In another study by Maeda et al., only one terrier suffering from TCC
was included [53], and two further studies by Mochizuki et al. did not mention the breeds that were
included [28,29].
The lower percentage of TCC with BRAF mutation (48%) found in the present study compared
to previous studies [26–29,53] may result from the lower number of included terriers in the study
cohort. Moreover, it must be considered that the genetic pool for certain breeds in the U.S. does not
necessarily parallel the genetic pool in Europe, and so, comparison of studies from the U.S. and Europe
may be difficult.
Due to the high specificity (100%) of BRAF mutation in canine TCC [26], analysis is recommended
in all breeds in the case of questionable, non-diagnostic cytological or histological samples. This avoids
further (necessary) invasive sampling. Due to the high sensitivity of BRAF mutation for terriers in our
study (73%) and the breed predisposition of terriers to suffer from TCC, testing for the presence of
BRAF mutation in this breed is recommended as an additional screening test independent of age [54].
Urine can be used for this purpose. It must be considered that only a positive result is diagnostic for
the presence of TCC. If BRAF mutation cannot be detected, the tumor is either not caused by this
mutation, no mutated cells are present in the specimen, or there is no TCC. Nevertheless, testing for
the presence of BRAF mutation can be used as a first, non-invasive test for the diagnosis of canine TCC.
5. Conclusions
Despite some similarities, there are also marked differences between canine and human TCC.
Testing for BRAF mutation in canine TCC is a sensitive diagnostic method especially in terriers
(73%) and recommended as a screening test. However, contrary to humans, the detection of BRAF
mutation in canine TCC is not a predictor for the histological grade, and a positive correlation between
histological grade and intensity of COX-2 expression was not found. The clinical and prognostic
relevance of the increased intensity of COX-2 expression in TCC with BRAF mutation in non-terrier
breeds has to be clarified in further studies.
Author Contributions: Conceptualization, H.A.-L.; methodology, J.M.G. and H.E.; formal analysis, S.M.;
investigation, J.M.G.; writing, original draft preparation, J.M.G.; writing, review and editing, H.A.-L. and R.K.;
visualization, J.M.G. All authors have reviewed the article and approved it for final submission.
Funding: This research received no external funding.
Acknowledgments: We thank Rachel Marschang and Doreen Girndt for their support.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Fulkerson, C.M.; Knapp, D.W. Management of transitional cell carcinoma of the urinary bladder in dogs:
A review. Vet. J. 2015, 205, 217–225. [CrossRef] [PubMed]
Vet. Sci. 2019, 6, 31 13 of 15
2. Mutsaers, A.J.; Widmer, W.R.; Deborah, W.; Knapp, D.W. Canine Transitional Cell Carcinoma. J. Vet.
Intern Med. 2003, 17, 136–144. [CrossRef] [PubMed]
3. Knapp, D.W.; Glickman, N.W.; DeNicola, D.B.; Bonney, P.L.; Lin, T.L.; Glickman, L.T. Naturally-occurring
canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder
cancer. Urol. Oncol. 2000, 5, 47–59. [CrossRef]
4. Knapp, D.W.; Ramos-Vara, J.A.; Moore, G.E.; Dhawan, D.; Bonney, P.L.; Young, K.E. Urinary bladder cancer
in dogs, a naturally occurring model for cancer biology and drug development. Ilar J. 2014, 55, 100–118.
[CrossRef] [PubMed]
5. Norris, A.M.; Laing, E.J.; Valli, V.E.; Withrow, S.J.; Macy, D.W.; Ogilvie, G.K.; Tomlinson, J.; McCaw, D.;
Pidgeon, G.; Jacobs, R.M. Canine bladder and urethral tumors: A retrospective study of 115 cases (1980–1985).
J. Vet. Intern. Med. 1992, 6, 145–153. [CrossRef] [PubMed]
6. Pantke, P. Diagnosis and treatment of transitional cell carcinoma of the lower urinary tract in the dog.
Kleintierprax 2018, 63, 76–92.
7. Knapp, D.W.; Ruple-Czerniak, A.; Ramos-Vara, J.A.; Naughton, J.F.; Fulkerson, C.M.; Honkisz, S.I.
A nonselective cyclooxygenase inhibitor enhances the activity of vinblastine in a naturally-occurring canine
model of invasive urothelial carcinoma. Bladder Cancer 2016, 2, 241–250. [CrossRef]
8. Knottenbelt, C.; Mellor, D.; Nixon, C.; Thompson, H.; Argyle, D.J. Cohort study of COX-1 and COX-2
expression in canine rectal and bladder tumours. J. Small Anim. Pract. 2006, 47, 196–200. [CrossRef]
9. Mohammed, S.I.; Bennett, P.F.; Craig, B.A.; Glickman, N.W.; Mutsaers, A.J.; Snyder, P.W.; Widmer, W.R.;
DeGortari, A.E.; Bonney, P.L.; Knapp, D.W. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor
response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Cancer Res. 2002, 62, 56–58.
10. Carvalho, S.; Stoll, A.L.; Priestnall, S.L.; Suarez-Bonnet, A.; Rassnick, K.; Lynch, S.; Schoepper, I.;
Romanelli, G.; Buracco, P.; Atherton, M.; et al. Retrospective evaluation of COX-2 expression, histological
and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy.
Vet. Comp. Oncol. 2017, 15, 1280–1294. [CrossRef]
11. Mohammed, S.I.; Khan, K.N.; Sellers, R.S.; Hayek, M.G.; DeNicola, D.B.; Wu, L.; Bonney, P.L.; Knapp, D.W.
Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot. Essent.
Fat. Acids 2004, 70, 479–483. [CrossRef]
12. Khan, K.N.; Knapp, D.W.; Denicola, D.B.; Harris, R.K. Expression of cyclooxygenase-2 in transitional cell
carcinoma of the urinary bladder in dogs. Am. J. Vet. Res. 2000, 61, 478–481. [CrossRef]
13. Lee, J.Y.; Tanabe, S.; Shimohira, H.; Kobayashi, Y.; Oomachi, T.; Azuma, S.; Ogihara, K.; Inokuma, H.
Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine
transitional cell carcinoma. Res. Vet. Sci. 2007, 83, 210–216. [CrossRef]
14. Mutsaers, A.J.; Mohammed, S.I.; DeNicola, D.B.; Snyder, P.W.; Glickman, N.W.; Bennett, P.F.; de Gortari, A.E.;
Bonney, P.L.; Knapp, D.W. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2
expression are not associated with the response of canine naturally occurring invasive urinary bladder
cancer to cyclooxygenase inhibitor therapy. Prostaglandins Leukot. Essent. Fat. Acids 2005, 72, 181–186.
[CrossRef]
15. Hurst, E.A.; Pang, L.Y.; Argyle, D.J. The selective cyclooxygenase-2 inhibitor mavacoxib (Trocoxcil™) exerts
anti-tumour effects in-vitro independent of cyclooxygenase-2 expression levels. Vet. Comp. Oncol. 2019.
[CrossRef]
16. Herr, H.W.; Shipley, W.U.; Bajorin, D.F. Cancer of the bladder. In DeVita VT, 6th ed.; Hellman, S.,
Rosenberg, S.A., Eds.; Principles and Practice of Oncology; Lippincott-Raven Publishers: Philadelphia,
PA, USA, 2001; pp. 139–141.
17. Shariat, S.F.; Matsumoto, K.; Kim, J.; Ayala, G.E.; Zhou, J.H.; Jian, W.; Benedict, W.F.; Lerner, S. Correlation
of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of
transitional cell carcinoma of the bladder. J. Urol. 2003, 170, 985–989. [CrossRef]
18. Agrawal, U.; Kumari, N.; Vasudeva, P.; Mohanty, N.K.; Saxena, S. Overexpression of COX2 indicates poor
survival in urothelial bladder cancer. Ann. Diagn. Pathol. 2018, 34, 50–55. [CrossRef]
19. Kömhoff, M.; Guan, Y.; Shappell, H.W.; Davis, L.; Jack, G.; Shyr, Y.; Koch, M.O.; Shappell, S.B.; Breyer, M.D.
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.
Am. J. Pathol. 2000, 157, 29–35. [CrossRef]
Vet. Sci. 2019, 6, 31 14 of 15
20. Tabriz, H.M.; Olfati, G.; Ahmadi, S.A.; Yusefnia, S. Cyclooxygenase-2 expression in urinary bladder
transitional cell carcinoma and its association with clinicopathological characteristics. Asian Pac. J. Cancer Prev.
2013, 14, 4539–4543. [CrossRef]
21. Manoharan, M.; Soloway, M.S. Optimal management of the T1G3 bladder cancer. Urol. Clin. N. Am. 2005, 32,
133–145. [CrossRef]
22. Reisz, P.A.; Laviana, A.A.; Chang, S.S. Management of High-grade T1 Urothelial Carcinoma. Curr. Urol. Rep.
2018, 19, 103. [CrossRef]
23. Chou, R.; Buckley, D.; Fu, R.; Gore, J.L.; Gustafson, K.; Griffin, J.; Grusing, S.; Selph, S. AHRQ comparative
effectiveness reviews. Emerging Approaches Diagnose and Treatment Non-Muscle-Invasive Bladder Cancer [Internet]
2015; Report No.: 15(16)-EHC017-EF; Agency for Healthcare Research and Quality (US): Rockville, MD,
USA, 2015.
24. Burkhari, N.; Al-Shamsi, H.O.; Azam, F. Update on the Treatment of Metastatic Urothelial Carcinoma.
Sci. World J. 2018, 2018, 5682078.
25. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3, 11–22.
[CrossRef] [PubMed]
26. Aupperle-Lellbach, H.; Grassinger, J.; Hohloch, C.; Kehl, A.; Pantke, P. Diagnostic value of the BRAF variant
V595E in urine samples, smears and biopsies from canine transitional cell carcinoma. Tierarztl. Prax. K. 2018,
46, 289–295.
27. Decker, B.; Parker, H.G.; Dhawan, D.; Kwon, E.M.; Karlins, E.; Davis, B.W.; Ramos-Vara, J.A.; Bonney, P.L.;
McNiel, E.A.; Knapp, D.W.; et al. Homologous mutation to human BRAF V600E is common in naturally
occurring canine bladder cancer—Evidence for a relevant model system and urine-based diagnostic test.
Mol. Cancer Res. 2015, 13, 993–1002. [CrossRef] [PubMed]
28. Mochizuki, H.; Kennedy, K.; Shapiro, S.G.; Breen, M. BRAF Mutations in canine cancers. PLoS ONE 2015.
[CrossRef] [PubMed]
29. Mochizuki, H.; Shapiro, S.G.; Breen, M. Detection of BRAF Mutation in urine DNA as a molecular diagnostic
for canine urothelial and prostatic carcinoma. PLoS ONE 2015. [CrossRef]
30. Dhillon, A.; Hagan, S.; Rath, O.; Kolch, W. Map kinase signalling pathways in cancer. Oncogene 2007, 26,
3279–3290. [CrossRef] [PubMed]
31. Mochizuki, H.; Breen, M. Comparative aspects of BRAF mutations in canine cancers. Vet. Sci. 2015, 2,
231–245. [CrossRef]
32. Boulalas, I.; Zaravinos, A.; Delakas, D.; Spandidos, D.A. Mutational analysis of the BRAF gene in transitional
cell carcinoma of the bladder. Int. J. Biol. Markers 2009, 24, 17–21. [CrossRef]
33. Marranci, A.; Jiang, Z.; Vitiello, M.; Guzzolino, E.; Comelli, L.; Sarti, S.; Lubrano, S.; Franchin, C.;
Echevarría-Vargas, I.; Tuccoli, A.; et al. The landscape of BRAF transcript and protein variants in human
cancer. Mol. Cancer 2017, 16, 85. [CrossRef] [PubMed]
34. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015, 161, 1681–1696.
[CrossRef] [PubMed]
35. Kimura, E.T.; Nikiforova, M.N.; Zhu, Z.; Knauf, J.A.; Nikiforov, Y.E.; Fagin, J.A. High prevalence of BRAF
mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF
signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63, 1454–1457. [PubMed]
36. Rajagopalan, H.; Bardelli, A.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Tumorigenesis:
RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418, 934. [CrossRef] [PubMed]
37. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma.
Nature 2014, 511, 543–550. [CrossRef] [PubMed]
38. Jin, M.; Long, Z.W.; Yang, J.; Lin, X. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF genetic
mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients. Pathol. Oncol. Res.
2018, 24, 45–57. [CrossRef]
39. Mochizuki, H.; Breen, M. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
Vet. Comp. Oncol. 2017, 15, 1598–1605. [CrossRef]
40. Bourn, J.; Cekanova, M. Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder
cancer cells in vitro. Drug Des. Devel. Ther. 2018, 13, 1727–1742. [CrossRef]
41. Fischer, A.H.; Jacobson, K.A.; Rose, J.; Zeller, R. Hematoxylin and eosin staining of tissue and cell sections.
Csh Protoc. 2008. [CrossRef]
Vet. Sci. 2019, 6, 31 15 of 15
42. Meuten, D.J.; Meuten, T.L.K. Tumors of the Urinary System. In Tumors of Domestic Animals, 5th ed.;
Meuten, D.J., Ed.; Wiley-Blackwell: Ames, IN, USA, 2017; Volume 1, pp. 632–688.
43. Ramos-Vara, J.A.; Miller, M.A. When tissue antigens and antibodies get along: Revisiting the technical aspects
of immunohistochemistry—The red, brown, and blue technique. Vet. Pathol. 2013, 51, 42–87. [CrossRef]
44. Hoffmann, C.; Bazer, F.W.; Klug, J.; Aupperle, H.; Ellenberger, C.; Schoon, H.A. Immunohistochemical and
histochemical identification of proteins and carbohydrates in the equine endometrium Expression patterns
for mares suffering from endometrosis. Theriogenology 2009, 71, 264–274. [CrossRef] [PubMed]
45. De Brot, S.; Robinson, B.D.; Scase, T.; Grau-Roma, L.; Wilkinson, E.; Boorjian, S.A.; Gardner, D.; Mongan, N.P.
The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and
histology. Oncol. Lett. 2018, 16, 1641–1649. [CrossRef]
46. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.;
Bottomley, W.; et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417, 949–954. [CrossRef]
[PubMed]
47. Stoeltzing, O.; Liu, W.; Fan, F.; Wagner, C.; Stengel, K.; Somcio, R.J.; Reinmuth, N.; Parikh, A.A.; Hicklin, D.J.;
Ellis, L.M. Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the
insulin-like growth factor-I receptor (IGF-IR) system. Cancer Lett. 2007, 258, 291–300. [CrossRef] [PubMed]
48. Doré, M. Cyclooxygenase-2 expression in animal cancers. Vet. Pathol. 2011, 48, 254–265. [CrossRef] [PubMed]
49. Allstadt, S.D.; Rodriguez, C.O., Jr.; Boostrom, B.; Rebhun, R.B.; Skorupski, K.A. Randomized phase III trial
of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract
transitional cell carcinoma in dogs. J. Vet. Intern. Med. 2015, 29, 261–267. [CrossRef] [PubMed]
50. Knapp, D.W.; Richardson, R.C.; Chan, T.C.; Bottoms, G.D.; Widmer, W.R.; DeNicola, D.B.; Teclaw, R.;
Bonney, P.L.; Kuczek, T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.
J. Vet. Intern. Med. 1994, 8, 273–278. [CrossRef] [PubMed]
51. Arantes-Rodrigues, R.; Pinto-Leite, R.; Ferreira, R.; Neuparth, M.J.; Pires, M.J.; Gaivão, I.; Palmeira, C.;
Santos, L.; Colaço, A.; Oliveira, P. Meloxicam in the treatment of in vitro and in vivo models of urinary
bladder cancer. Biomed. Pharmacother. 2013, 67, 277–284. [CrossRef]
52. Meyer, P.; Sergi, C.; Garbe, C. Polymorphisms of the BRAF gene predispose males to malignant melanoma.
J. Carcinog. 2003, 2, 7. [CrossRef]
53. Maeda, S.; Tomiyasu, H.; Tsuboi, M.; Inoue, A.; Ishihara, G.; Uchikai, T.; Chambers, J.K.; Uchida, K.;
Yonezawa, T.; Matsuki, N. Comprehensive gene expression analysis of canine invasive urothelial bladder
carcinoma by RNA-Seq. BMC Cancer 2018, 18, 472. [CrossRef]
54. Breen, M.; Wiley, C. Flüssigbiopsie—Die Zukunft der Tumordiagnostik. Vet. Focus 2018, 28, 39–45.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
